#1 - Merck (NYSE:MRK)
One of the biggest stories in the pharmaceutical sector was the announcement that Merck (NYSE: MRK) was able to report stellar results on a late-stage study for its Covid-19 therapy, molnupiravir. The pill, which the company developed in partnership with Ridgeback Biotherapeutics, is likely to be a huge commercial success should it receive emergency use authorization.
This is igniting an intense debate over whether a safe and effective pill to treat Covid-19 symptoms will render vaccination efforts obsolete. For investors looking to 2022, I believe a “both/and” approach is warranted.
MRK stock gapped up nearly 10% on the announcement. But the stock is giving up some of those gains. The consensus opinion for MRK stock forecasts a 15% gain. But recent opinions that have been issued since the announcement of its Covid-19 pill suggest the stock could have even further to climb. Plus, the company reports earnings at the end of October and the stock may receive further upgrades in advance of, and immediately following the report.
About Merck & Co., Inc.
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Read More - Current Price
- $98.05
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 13 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $127.13 (29.7% Upside)
